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HepatitisCvirus (HCV) isclassified intosevenmajorgenotypesand67subtypes.Recentstudieshaveshownthat inHCVgenotype1-infected
patients, responserates toregimenscontainingdirect-actingantivirals (DAAs)aresubtypedependent.Currentlyavailablegenotypingmeth-
odshave limitedsubtypingaccuracy.Wehaveevaluatedtheperformanceofadeep-sequencing-basedHCVsubtypingassay,developedfor the
454/GS-Juniorplatform, incomparisonwiththoseof twocommercialassays (VersantHCVgenotype2.0andAbbottReal-timeHCVGeno-
typeII)andusingdirectNS5Bsequencingasagoldstandard(direct sequencing), in114clinical specimenspreviously testedbyfirst-genera-
tionhybridizationassay(82genotype1and32withuninterpretableresults).Phylogeneticanalysisofdeep-sequencingreadsmatchedsubtype
1callingbypopulationSangersequencing(69%1b,31%1a) in81specimensandidentifiedamixed-subtype infection(1b/3a/1a) inonesam-
ple.Similarly, amongthe32previously indeterminatespecimens, identicalgenotypeandsubtyperesultswereobtainedbydirectanddeep
sequencing inallbut foursampleswithdual infection. Incontrast,bothVersantHCVGenotype2.0andAbbottReal-timeHCVGenotypeII
failedsubtype1calling in13(16%)sampleseachandwereunable to identify theHCVgenotypeand/orsubtype inmore thanhalfof thenon-
genotype1samples.Weconcludedthatdeepsequencing ismoreefficient forHCVsubtypingthancurrentlyavailablemethodsandallows
qualitative identificationofmixed infectionsandmaybemorehelpfulwithrespect to informingtreatmentstrategieswithnewDAA-contain-
ingregimensacrossallHCVsubtypes.
There are seven confirmed hepatitis C virus (HCV) genotypes,with whole-genome nucleotide sequences differing by30%,
and each can be further subdivided into related subtypes (67 con-
firmed), with nucleotide sequence divergence of between 15%and
30% (1).
Genotype identification has long been used in clinical practice,
because major genotypes have different response rates and require
different doses and durations of pegylated interferon and ribavirin
(PR) treatment. In contrast, until recently, subtype identificationwas
mainly used in epidemiological studies. However, both in vitro stud-
ies and clinical trials with different classes of direct-acting antiviral
(DAA) agents (NS3 protease, NS5A-, and nucleos[t]ide and non-
nucleos[t]ide NS5B-polymerase inhibitors), given with PR or in in-
terferon-free combinations, have shown lower response rates for
HCV genotype 1a than for HCV genotype 1b (2–8). Moreover, at
least for HCV genotype 1, both the frequency and the pattern of
resistance to different DAA classes are subtype specific (9). A strik-
ing example is the NS3-Q80K polymorphism, naturally found in
30%ofnaive subtype1apatientsbut in1%of subtype1bpatients
(10), which conveys 30%-to-40%-lower sustained-virologic-re-
sponse (SVR) rates to the macrocyclic protease inhibitor simeprevir
(2). Similarly, all subtype 1g sequences identified naturally carry a
mutationconferring resistance to linearNS3protease inhibitors (11).
Subtype-specific differences in the genetic barrier to resistance
appear to correlate to the RNA-dependent RNA polymerase mu-
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tational bias toward transitionmutations anddifferences in codon
usage characteristic of each subtype rather than to the degree of
genetic diversity of the viral population (12–15). In addition,
coinfection with two or more HCV strains of different genotypes
or subtypes is a common finding in some high-risk groups. Re-
searchers who performed several studies in persons who inject
drugs (PWID) and among men who have sex with men (MSM)
have reported the simultaneous presence of two or more HCV
subtypes in 25% to 39% of incident infections (16–19). Taken
together, the findings of the subtype-specific response to different
classes of DAA and of the frequency of multiple infections among
groups with the highest incidence and prevalence of HCV infec-
tion make accurate HCV subtyping, including detection of mixed
infections, an essential tool to optimize current and future treat-
ment regimens.
Currently available genotyping methods based on reverse hy-
bridizationwith subtype-specific primers and probes targeting the
5= untranscribed region (UTR) and core regions (Versant HCV
Genotype 2.0 system; Siemens), and Real-time (Rt) PCR assays
based on 5=UTR andNS5B sequencing (Abbott HCVGenotype II
assay), accurately differentiate major HCV genotypes in the ma-
jority of cases and are widely used because of their technical sim-
plicity. However, these assays have not been designed to confi-
dently identify mixed infections, and their ability to accurately
discriminate HCV subtypes other than 1a and 1b is very limited
(20–27).
We have evaluated the analytical performance of a deep-se-
quencing-based HCV genotyping assay, targeting NS5B, using a
readily available platform (454/GS-Junior; Roche), in 114 sam-
ples, in comparison with two commercially available techniques,
using population Sanger sequencing and phylogenetic analysis of
a 339-nucleotide (nt)-long NS5B fragment as a reference (28).
MATERIALS AND METHODS
Patients. Coded serum samples from 114 HCV-infected patients previ-
ously tested by first-generation line probe assay (Inno-LiPA v1.0) were
used without any patient-associated demographic and clinical informa-
tion. Eighty-two were genotype 1, and 32 had no subtype calling by Inno-
LiPA analysis. All specimens were collected and processed as recom-
mended and stored at 80°C. Patient samples were collected from
different hospitals of the National Spanish Health System with the behest
of selecting samples that are difficult to classify using commercial tech-
niques. In addition to genotype 1 samples, we also asked for samples other
than genotype 1 to cover as many subtypes as possible. Taking advantage
of the Tropical Medicine outpatient clinics in Hospital Carlos III in Ma-
drid, we received 26 samples from Spanish people, most of them of equa-
torial Guinean origin. The vast majority of them did not have a history of
intravenous drug use (IDU).
Genotyping specimens. All specimens but two were subtyped using
four methods, deep sequencing on a 454/GS-Junior platform, direct
Sanger sequencing, and two commercial assays, Versant HCV Genotype
2.0 and Real-time HCV Genotype II. PCR-amplified products were se-
quenced in parallel by direct and deep sequencing. For subtyping using
the commercially available procedures, serum samples were processed
strictly following the manufacturing instructions.
RNA extraction. HCV RNA was extracted from 650 l of plasma or
serum by automatic RNA extraction using a total nucleic acid isolation
(TNAI) kit (AmpliPrep system; Roche Diagnostics, West Sussex, United
Kingdom) ormanual RNA extraction (140l) using aQIAamp viral RNA
minikit (Qiagen, Hilden, Germany). The measures to prevent contami-
nation suggested by Kwok and Higuchi were strictly applied (29).
Target region and primers. The NS5B target for HCV subtyping was
a 339-nucleotide (nt)-long region spanning nt 8280 to 8618, according to
the isolate H77 data available in GenBank under accession number
AF009606 (30). Primer and PCR condition data have been deposited un-
der patent number EP13382278 and are reported in the next sections.
In cases of low viral load or low RNA quality, when NS5B was impos-
sible to amplify, we sequenced the 5= core region spanning nt 45 to 490 for
reverse transcription-PCR (RT-PCR) and nt 146 to 490 for heminested
PCR (Fig. 1). The specific primers for RT-PCR were forward primer
UTR45 (5=CTGTGAGGAACTACTGTCTTCACGCAG3=) and reverse
primer Cor490 (5=CTAGTCGCGCGCACACCCA3=). The specific prim-
ers for heminested PCR were forward primer M13UTR146 (5=GTTGTA
AAACGACGGCCAGTGTCTGCGGAACCGGTGAGTACA3=) and re-
verse primer M13Core490 (5=CACAGGAAACAGCTATGACCCTAGTC
GCGCGCACACCCA3=). The enzymes and amplification conditions were
the same as for the NS5B amplicon (see below). Only 4 samples (P-IND-6,
-13, -14, and -17) out of 114 were classified by the 5= core region.
RT-PCRamplification fordirect anddeep sequencing.The complete
process is depicted in Fig. 1. Briefly, reverse transcription was performed
using a Transcriptor One Step reverse RT-PCR kit (Roche Applied Sci-
ence, Basel, Switzerland), 20 pmol of the downstream primer labeled
5Bo8707, and 20 pmol of the upstream primer labeled 5Bo8254 (Table 1).
See the supplemental material for reaction details. A final product of 454
nucleotides is obtained.
Heminested PCR was performed using a FastStart High Fidelity PCR
System, dNTPack (Roche Applied Science, Basel, Switzerland), 5 l from
the PCR, and a pair of upstream (13N5Bo8254) and downstream (13N5
Bo8641) primers (Table 1). Nested PCR was performed using the same
conditions as were used for first PCR. A final product of 428 nucleotides
(including primers) was obtained.
To identify every patient, the final product of heminested amplifica-
tionwas subjected to 15 cycles of reamplification using primers composed
of a complementary universal M13 primer (either upstream or down-
stream) followed by a Roche’s ValidatedMultiplex IDentifier (MID) with
oligonucleotide A or B at the 5= or 3= end of the upstream or downstream
primer, respectively (Fig. 1). A final product of 498 nucleotides (including
primers) was obtained.
Amplification products were analyzed by 1.8% agarose gel electropho-
resis, and negative controls (amplifications in the absence of RNA) were
included in parallel to ensure the absence of contamination by template
nucleic acids. The final nested amplification yielded 498-nt fragments that
were purified in agarose gel using a QIAquick gel extraction kit (Qiagen,
Valencia, CA, USA), quantified using the PicoGreen assay (Invitrogen,
Carlsbad, CA, USA), and quality analyzed using a BioAnalyzer DNA 1000
LabChip (Agilent, Santa Clara, CA, USA) prior to sequencing.
Onealiquotof eachPCRproductwas subjected toSanger sequencing and
another to ultradeep pyrosequencing (UDPS) subtyping as follows. The se-
quencesobtainedbyeitheroneor theotherof the technologieswere subjected
to phylogenetic analysis using recommended reference sequences (1).
Direct Sanger sequencing. The PCR product was directly sequenced
using a BigDye Terminator v1.1 cycle sequencing kit and a capillary au-
tomated DNA-sequencing instrument (Applied Biosystems, Foster City,
CA,USA). Consensus (average) sequences obtained by population Sanger
sequencing were subjected to phylogenetic analysis (see below).
Deep sequencing. In order to facilitate the translation of deep se-
quencing from basic research to a health care routine diagnostic labora-
tory, most of the manual processing steps have been automated using a
programmed Evo75 robot device (Tecan, Männedorf, Switzerland).
Briefly, after nested PCR amplification, the final product is flanked by
universal M13 sequences in both ends. The last PCR amplification is per-
formed in a 96-well plate previously preloaded with a lyophilized univer-
sal primer pair composed of an M13 universal primer plus MID plus
oligonucleotide A or B (454 sequencing) (M13-MID_A/B primer) (TIB
Molbiol, Berlin, Germany). Each patient sample requires a different MID
sequence. The PCR product of this amplification is then automatically
Quer et al.
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purified using Ampure Agencourt AMPure XPmagnetic beads (Beckman
Coulter, Brea, CA, USA) and quantified using a fluorometric titration
Quant-iT PicoGreen double-stranded DNA (dsDNA) kit (Life Technol-
ogies, Eugene, OR, USA) in an Infinity fluorometer (Tecan, Männedorf,
Switzerland) and equimolecular pooling and a final enrichment step using
an automatedREMeSTARletHamiltonworkstation (HamiltonRobotics,
Reno, NV, USA).
Massive sequencing was performed in the 454/GS-Junior platform
(Roche, Branford, CT, USA), using titanium chemistry (GS-Junior Tita-
nium Sequencing kit), which enables sequencing of 400-to-500-nt frag-
ments. An average of 1,250 sequences (reads) were obtained (minimum
[min], 200; maximum [max], 5,240).
The fasta file from the GS-Junior is demultiplexed to obtain a fasta file
for each sample and strand. Reads not identified by MID and/or primer
FIG 1 Scheme of the NS5B amplification protocol for HCV subtyping either using direct PCR Sanger sequencing or UDPS subtyping. Specific and universal
primers are specified in each amplification step. NCR, noncoding region; nts, nucleotides; Oligo, oligonucleotide(s).
TABLE 1 Primers used for RT-PCR and heminested amplifications
Primer type Primer name Primer sequence (5=–3=)
RT-PCR
Upstream 5Bo8254 CNTAYGAYACCMGNTGYTTTGACTC
Downstream 5Bo8707 TTNGADGAGCADGATGTWATBAGCTC
Heminesteda
Upstream 13N5Bo8254 GTTGTAAAACGACGGCCAGTTTNGADGAGCADGATGTWATBAGCTC
Downstream 13N5Bo8641 CACAGGAAACAGCTATGACCGARTAYCTGGTCATAGCNTCCGTGAA
a Heminested primers are composed of universal M13 forward (M13f) and M13 reverse (M13r) primers at the 5= ends followed by a specific fragment (italic typeface)
complementary to the HCV PCR-amplified fragment.
HCV Subtyping by UDPS
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are discarded. The allowances are one mismatch on the MID, two in the
specific primer, and three on the universal primer M13, with no indels.
Sequences not covering the full amplicon (positions 8280 to 8618) or
showing more than 2 Ns or 3 gaps are discarded (31). MIDs and primers
are trimmed. The reverse-strand sequences are reverse complemented
and joined with the forward strand sequences of the same sample. Unique
sequences (haplotypes) are identified and their frequencies computed as
the number of observed reads.
Then follows a process of clustering of haplotypes to select those to be
subtyped in each sample. The dominant haplotype is selected, and all
those sequences with a pairwise identity above 90% with respect to this
haplotype are clustered. The dominant haplotype is taken as the represen-
tative sequence of the cluster (the centroid) and the centroid frequency as
representative of the results of the addition of the frequencies of all clus-
tered haplotypes. This process is done recursively until no haplotypes are
left. The result is a set of representative haplotypes (centroids) with their
observed population frequencies. The threshold of 90% identity was se-
lected on the basis of the minimum observed distance between pairs of
reference sequences of different subtypes.
Subtype calling. Each UDPS haplotype centroid, or population
Sanger sequence, is multiply aligned with the set of reference sequences
(1) using Clustalo. This multiple alignment provides a matrix of genetic
distances with the Kimura-80 model (K80) with a gamma parameter of
0.42. The query haplotype is classified as the subtype with the nearest
reference sequence. For subtypes with multiple reference sequences, two
other distances to the query haplotype are computed: the average and the
farthest in each subtype. These distances are used as clustering quality
scores. A high-quality clustering result is produced when the subtypings
according to the shortest, the average, and the farthest distances coincide.
A confidence score is produced by 200 cycles of bootstrap analysis on the
multiple alignment obtained for each query haplotype and subtyping ac-
cording to the shortest distance. Query haplotypes classified with discor-
dant shortest-distance and average-distance subtyping or with bootstrap
scores below 70 are tagged as dubious.
A minimum of 5 reads and of 1% abundance is imposed to infer a
mixed infection by a minority subtype. As a further step, a fuzzy-logic-
based expert system is being developed to infer recommendations based
on the sequencing coverage, percentage of minority subtypes, and classi-
fication by the nearest distance and the average distance and by the boot-
strap confidence level. This is the matter of a publication in preparation.
The data analysis system consists of four Rmodules, implementing the
demultiplexingmodule, the quality filter and haplotype selectionmodule,
the phylogenetic analysis module, and the expert system module. The
scripts use the Bioconductor packages Biostrings and ape.
HCV genotyping using commercial available methods. (i) Versant.
The HCV Genotype 2.0 assay (LiPA HCV v.2.0; Siemens Healthcare Di-
agnostics, Eragny, France) is a line probe assay based on a reverse hybrid-
ization of biotinylated products targeting the 5= UTR and a fragment of
the core region which are hybridized to immobilized oligonucleotide
probes in nitrocellulose strips that are specific for the 5=-UTR core regions
of the six genotypes.
(i) Abbott Real-time. The HCV Genotype II assay software, version
1.0 (Abbott Molecular, Des Plaines, IL, USA), is based on Real-time PCR
targeting the 5= UTR and the NS5B gene for discrimination between ge-
notypes 1a and 1b. The assay uses rTth DNA polymerase and four sets of
PCR primers to amplify the 5=-UTR region, NS5B subtype 1a, NS5B sub-
type 1b, and an heterologous internal control, respectively. The assay uses
fluorescence-labeled oligonucleotide probes specific for genotypes 1 to 6
and subtypes 1a and 1b, in three separate reactions, one to detect geno-
types 1a and 3, the second for genotypes 2, 1b, and 1, and the third for
genotypes 4, 5, and 6 (Abbott Rt HCV Genotype II insert package).
Statistical analysis.Rates and proportions were analyzed by the bino-
mial and Fisher exact tests. A P value of 0.05 was considered statistically
significant.
Ethics statement. The study has been approved by the Ethical Com-
mittees (CEIC) of Vall d’Hebron and of the clinical centers that have
provided samples. All samples were collected from adults who provided
the consent required to perform the study.
Nucleotide sequence accession numbers. The sequences obtained in
this study have been deposited in GenBank under accession numbers
SAMN03198770 (for patient P01) to SAMN03198883 (for patient PIND32).
All sequencesdeposited inGenBankbelong toNS5Bexcept SAMN03198857,
SAMN03198864, SAMN03198865, and SAMN03198868, which belong to
the 5= core region (from nt 146 to nt 490).
RESULTS
As shown in Table 2, among the 82 HCV genotype 1 samples, 25
were subtyped as 1a and 57 as subtype 1b, by both direct and deep
sequencing. The subtype could not be established in 13 (16%)
samples by either the Versant HCV Genotype 2.0 or the Abbott
Rt-HCV Genotype II method. Of the 25 subtype 1a samples, 5
(20%) and 7 (28%) could not be subtyped by the Versant/Siemens
and Rt-HCV/Abbott methods, respectively. Similarly, of the 57
subtype 1b samples, 8 (14%) and 6 (10%) could not be subtyped
by those techniques, respectively.
Interestingly, one sample which was classified as 1b by popu-
lation Sanger sequencing and by both commercial techniques was
found to be a mixed infection of HCV subtypes 1b (43%), 3a
(35%), and 1a (22%) by our deep-sequencing-based high-resolu-
tion assay. This patient had no history of IDU.
Among the 32 untyped non-genotype 1 samples, 3 were found
to be genotype 2, 4 to be genotype 3, 23 to be genotype 4, and 1
TABLE 2 Comparison of genotyping results obtained by the four
methods in genotype 1 specimens
Patient code
Genotyping result
Direct NS5B
sequencing
Versant HCV
Genotype 2.0
Abbott Real
time HCV
genotype II
UDPS HCV
Subtyping
454/GS-Juniora
P1–P17 1a 1a 1a 1a
P18–P61 1b 1b 1b 1b
P62 1a 1 1 1a
P63 1a 1a 1 1a
P64 1a 1 1a 1a
P65 1a 1a 1 1a
P66 1a 1 1 1a
P67 1a 1 1 1a
P68 1a 1 1 1a
P69 1a 1a 1 1a
P70 1b 1 1b 1b
P71 1b 1 1 1b
P72 1b 1 1b 1b
P73 1b 1 1b 1b
P74 1b 1 1b 1b
P75 1b 1 1 1b
P76 1b 1b 1 1b
P77 1b 1b 1b 1b 3a 1ab
P78 1b 1b 1 1b
P79 1b 1/1a 1b 1b
P80 1b 1 1b 1b
P81 1b 1b 1 1b
P82 1b 1b 1 1b
a P 0.001 for the comparison of UDPS with Versant HCV Genotype 2.0 and Abbott
Real time HCV genotype II techniques.
b Sample with mixed infection. Relative proportions of subtypes: 1b, 43%; 3a, 35%;
1a, 20%.
Quer et al.
222 jcm.asm.org January 2015 Volume 53 Number 1Journal of Clinical Microbiology
 o
n
 M
ay 10, 2016 by UAM
/SERVICIO
 DE DO
CUM
ENTACIO
N
http://jcm.asm.org/
D
ow
nloaded from
 
each to be genotype 5 and genotype 6 by direct sequencing. Table
3 shows the results obtained by each technique compared with
direct sequencing for each sample. Again, absolute concordance
in HCV subtype results was found between direct and deep se-
quencing in 28 (88%) of the 32 samples. In the four remaining
samples, despite the fact that the population Sanger sequencing
results correlated with the master sequence identified by deep se-
quencing, this new technology showed mixed infections by two
different HCV subtypes. In this sense, it must be kept inmind that
this method is not able to detect DNA mixtures. The Abbott Rt-
HCV Genotype II technique was the other one that identified a
mixed infection in two of the three cases (66%) whereas popula-
tion Sanger sequencing and Versant HCV Genotype 2.0 did not.
The two commercial available genotyping methods used were
unable to identify the HCV subtype of the majority of these sam-
ples. VersantHCVGenotype 2.0matched the genotype in 14 of 32
samples (44%) and the subtype in 6 of the 32 samples (19%) and
gave subtype results approaching identification (2a/c or 4a/c/d) in
5 of the 32 samples (16%), indeterminate subtype results in 15 of
32 samples (47%), and negative or misclassification results in 2 of
the 32 samples (6%). In the remaining four samples (12%), it gave
the genotyping result. Abbott Rt-HCV Genotype II, which is not
designed to differentiate subtypes other than 1a/1b, correctly
identified the HCV genotype in 12 of 30 samples (40%), none of
the subtypes resulted in a misclassification result in 15 of the 30
samples (50%), and the assay was able to identify mixed infection
in two of three samples tested.
It is interesting that 4 of the 32 indeterminate samples were
mixed-infection samples as detected by deep HCV subtyping.
Two of the four patients showing mixed infections had a history
of IDU.
DISCUSSION
The present report describes the performance of a subtyping assay
based on phylogenetic analysis of reads obtained by deep sequenc-
ing of a NS5B fragment in samples poorly characterized by a first-
generation hybridization assay, in comparison with two widely
used commercial assays. The collection of samples used to validate
themethodology described here does not necessarily represent the
current distribution of HCV genotypes/subtypes in Spain, since
samples that cover asmany subtypes as possible and are difficult to
subtype by first-generation Inno-LiPA were selected.
Similarly to what happens with Sanger sequencing or commer-
cial techniques for genotyping, improper storage of serum sam-
ples or RNA manipulation may cause a decay in viral load and
RNAdegradation giving a negative amplification result. In cases of
negative amplification from a chronically HCV-infected patient,
the quality of the sample is studied by performing an RT-PCR–
nested amplification of the 5=-UTR region. Even in cases of correct
manipulation, we have observed that low viral loads (below 104
copies/ml) represent an important limitation with respect to suc-
cessful PCR amplification and sequencing.
Our assay correctly identified the HCV subtype in all samples,
matching the results of direct sequencing, and was able to identify
the presence of different HCV subtypes, and their relative propor-
tions, in five samples with mixed infections. In contrast, the two
commercial assays, despite identifying all genotype 1 samples,
failed HCV-1 subtype calling in 13 (16%) samples each. In addi-
tion, both assays failed genotype/subtype calling in half of the 32
samples with non-1 HCV genotypes. These results are similar to
those reported in previous studies, in which uninterpretable or
indeterminate genotype calls were observed in 2% to 45% of sam-
ples (especially in non-genotype 1 infections) and theHCV-1 sub-
type could not be assigned in 2% to 15% of samples (20–25, 27,
32–34).
Although the limitations of currently available genotyping as-
says for HCV-1 subtype classification may have not been a major
problem with the first-wave DAAs, accurate HCV subtyping and
identification of mixed infections are likely to play a major role in
patient management in the immediate future for several reasons.
First, under FDA guidance, indications for use of the recently
approved protease inhibitor simeprevir (Olysio; Janssen Thera-
peutics, Titusville, NJ) on the package insert endorse baseline
screening ofHCV-1a-infected patients for the presence of theNS3
Q80K polymorphism, thus requiring prior knowledge of the
HCV-1 subtype. A requirement for unequivocal subtype 1 calling
before treatment might also be endorsed for some interferon-free
regimens which are currently being investigated in clinical trials
TABLE 3 Comparison of genotyping results obtained by the four
methods in 32 specimens with indeterminate genotypes by first-
generation hybridization assay (LiPa 1.0)a
Patient code
Genotyping result
Direct NS5B
sequencing
Versant HCV
Genotype 2.0
Abbott Real
time HCV
genotype II
UDPS HCV
Subtyping 454/GS-
Junior (% of total)
P-IND-1 2c 2a/c 2 2c
P-IND-2 2c 2a/c 2 2c
P-IND-3 3a 3 3 3a
P-IND-4 3a 3a ND 3a
P-IND-5 3a 3a 3 3a
P-IND-6 3a 3a 3 3a
P-IND-7 4a 4 4 4a
P-IND-8 4a 4a/c/d 4 4a
P-IND-9 4d 4 4 4d
P-IND-10 4d 4 4 4d
P-IND-11 4d 4a/c/d 4 4d
P-IND-12 4d 4a/c/d 4 4d
P-IND-13 4f 4f 4 5b 4f
P-IND-14 4f 4f 4 5b 4f
P-IND-15 4f Ind 4 5b 4f
P-IND-16 4f Ind 4 5b 4f
P-IND-17 4f Ind 4 5b 4f
P-IND-18 4f Ind 4 5b 4f
P-IND-19 4f Ind 4 5b 4f
P-IND-20 4f Ind 4 5b 4f
P-IND-21 4f Ind 4 5b 4f
P-IND-22 4f Ind 5 4f
P-IND-23 4f Ind 5 4f
P-IND-24 4f Ind 5 4f
P-IND-25 4f Ind 5 4f
P-IND-26 4r Ind 1 4 4r
P-IND-27 5a 5a 5 5a
P-IND-28 6c Neg 5 6c
P-IND-29 4d Ind 4 4d (72) 1a (28)
P-IND-30 2j 2 ND 2j (95) 4f (5)
P-IND-31 4p Ind 3 4 4p (53) 3a (47)
P-IND-32 4d Ind 1a 4 4d (87) 1a (13)
a P-IND, patient samples with an indeterminate genotype (by first-generation Inno-
LiPA). Ind, indeterminate result. Such results can be interpretable by facultative
analysis. ND, not done; Neg, no PCR amplification.
b 4 5, genotype 4 and reactivity with genotype 5.
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restricted toHCV-1b-designated subjects only (ClinicalTrials.gov
identifiers NCT01732796, NCT01728324, NCT01581 203, and
NCT01767116).
Second, the striking differences between subtypes 1a and 1b in
genetic barriers to resistance to most DAAs (4, 12, 35), and the
presence of naturally occurring resistance mutations in other
HCV-1 subtypes (11), strongly suggest that a similar phenomenon
is likely to occur with other genotypes, especially for genotypes 2,
4, and 6 because of their high subtype diversity (11 subtypes for
G2, 17 for G4, and 24 for G6). Unfortunately, subtype-specific
resistance data for other genotypes remain scarce (36–39).
This limited knowledge is especially relevant for genotype 4
due to its high subtype diversity (1, 40) and because it accounts for
most infections in Egypt (the country with the highest prevalence
and incidence of HCV) (41), the Middle East, and sub-Saharan
Africa. In this regard, in a recent study, Newman et al., using
whole-genome deep sequencing, identified combined dominant
NS3 andNS5B resistancemutations in a restricted subset of geno-
type 4 subtypes (4g, 4k-r, and 4v), further reinforcing the require-
ment for accurate subtype calling in clinical practice (40).
Third, reliable identification of mixed-type infections, fre-
quently found in PWID and, to a lesser extent, in individuals un-
dergoing frequent health care procedures in resource-limited ar-
eas, is beyond the capability of current assays. Since injecting-drug
use is still the major driving force of the uncontrolled HCV epi-
demic throughout the world (42–44), any attempt at global erad-
ication of HCV through interferon-sparing treatment will have to
target PWID and deal with a high proportion of mixed infections.
In this setting, accurate subtyping and identification of mixed in-
fections by deep-sequencing methods will be of critical impor-
tance to enhance treatment success and minimize the develop-
ment and rapid spread of drug-resistant viruses. Indeed, use of
genotype-specific therapies might result in virological failure in
individuals withmixed-type infection, which is relevant due to the
cost of the new interferon-free regimens.
Finally, as HCV treatment shifts to more-effective and better-
tolerated all-oral regimens and treatment uptake becomes wide-
spread, suboptimal treatment adherence, rather than problems
associated with potency and genetic barriers to resistance, may
become amore frequent cause of treatment failure in clinical prac-
tice. Since even regimens containing potent agents with a high
barrier to resistance, such as nucleos(t)ide NS5B polymerase in-
hibitors, have been shown to select subtype-dependent resistance
(45, 46), in addition to fixed-dose formulations and reinforce-
ment of adherence, reliable subtyping may help identify patients
requiring closer surveillance and facilitate resistance testing in
cases of treatment failure.
There were several limitations in our study. First, the limited
number of samples with some HCV genotypes precluded evalua-
tion of test performance in rareHCV subtypes. Second, since both
our deep-sequencing assay and the reference method for final
subtype assignment target only an NS5B fragment, the possi-
bility that some discrepancies between NS5B and 5=-UTR/
core-based assays in genotype/subtype calling were in fact ex-
amples of intergenotypic recombinants (47) cannot be ruled
out. Although sequencing of an additional structural gene
(such as core/E1) might suggest the presence of an HCV re-
combinant, full-genome sequencing would be required for its
confirmation using a PCR-free technology (40, 48).
Despite these limitations, however, our results indicate that
deep sequencing ofNS5B on a readily available platform, followed
by a filtering process and a phylogenetic classification of sequence
reads, is a very reliable method for HCV subtyping that could
rapidly move from research to clinical diagnostic laboratories to
replace classical sequencing methods in resolving indeterminate
subtype results of existing assays. Furthermore, deep sequencing is
likely to become the method of choice for HCV subtyping when
interferon-sparing regimens reach high-risk population groups.
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